Wall Street Zen Downgrades Aldeyra Therapeutics (NASDAQ:ALDX) to Sell

Aldeyra Therapeutics (NASDAQ:ALDX) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Several other brokerages have also issued reports on ALDX. BTIG Research reiterated a “buy” rating on shares of Aldeyra Therapeutics in a report on Tuesday. HC Wainwright restated a “neutral” rating and issued a $2.00 target price (down from $10.00) on shares of Aldeyra Therapeutics in a research note on Wednesday. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $5.50.

Aldeyra Therapeutics Stock Performance

Shares of ALDX opened at $1.81 on Friday. The company has a market capitalization of $108.93 million, a PE ratio of -3.18 and a beta of 0.97. The company’s 50 day moving average price is $4.78 and its 200 day moving average price is $5.00. Aldeyra Therapeutics has a 52 week low of $1.07 and a 52 week high of $6.81.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its earnings results on Friday, February 27th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03. On average, equities analysts forecast that Aldeyra Therapeutics will post -0.92 earnings per share for the current fiscal year.

Insider Activity at Aldeyra Therapeutics

In other Aldeyra Therapeutics news, Director Richard Douglas purchased 70,000 shares of the company’s stock in a transaction dated Thursday, March 19th. The shares were bought at an average price of $1.40 per share, for a total transaction of $98,000.00. Following the purchase, the director directly owned 195,000 shares in the company, valued at $273,000. This trade represents a 56.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. 9.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Aldeyra Therapeutics

A number of large investors have recently bought and sold shares of ALDX. The Manufacturers Life Insurance Company lifted its position in Aldeyra Therapeutics by 10.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,074 shares of the biotechnology company’s stock worth $77,000 after acquiring an additional 1,972 shares during the last quarter. Rhumbline Advisers grew its position in shares of Aldeyra Therapeutics by 2.7% in the second quarter. Rhumbline Advisers now owns 77,494 shares of the biotechnology company’s stock valued at $297,000 after purchasing an additional 2,018 shares during the last quarter. Brighton Jones LLC increased its stake in shares of Aldeyra Therapeutics by 11.4% in the third quarter. Brighton Jones LLC now owns 19,945 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 2,046 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Aldeyra Therapeutics by 1.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 152,787 shares of the biotechnology company’s stock worth $791,000 after purchasing an additional 2,309 shares during the period. Finally, Federation des caisses Desjardins du Quebec lifted its position in shares of Aldeyra Therapeutics by 25.8% during the 4th quarter. Federation des caisses Desjardins du Quebec now owns 12,187 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 2,500 shares during the last quarter. 59.71% of the stock is currently owned by institutional investors.

More Aldeyra Therapeutics News

Here are the key news stories impacting Aldeyra Therapeutics this week:

• Positive Sentiment: Insider buying: Director/insider Michael Alfieri increased his stake, purchasing 5,000 shares at ~$1.42 on March 18 — a modest signal of insider conviction that can be viewed as supportive amid the sell-off. SEC Filing: Insider Purchase
• Neutral Sentiment: Broker note status: HC Wainwright reaffirmed a Neutral rating and a $2.00 target while publishing updated model revisions. The Neutral stance limits upside endorsement from that shop but keeps coverage steady. HC Wainwright Reaffirms Neutral Rating
• Negative Sentiment: Analyst cuts: HC Wainwright sharply reduced EPS forecasts across 2026–2030 (Q4 2026 from $0.27 to ($0.02); FY2026 to ($0.44); FY2027 to ($0.27); FY2028–2030 also lowered). The revisions signal weaker expected profitability and push down research-driven valuation support. HC Wainwright Research Note
• Negative Sentiment: Lawsuits / investigations: Multiple law firms (Pomerantz; Levi & Korsinsky and others) have launched securities-fraud probes and class-action recruitment, alleging management misstatements around reproxalap’s efficacy and approval prospects. Litigation risk and potential disclosures raise investor uncertainty. Pomerantz Investigation Notice Levi & Korsinsky Alert
• Negative Sentiment: Market reaction / put buying: Heavy put-option activity and a multi-day slump (reports cite ~67% decline since Tuesday) indicate aggressive bearish positioning and rapid de-risking by traders following the FDA Complete Response Letter for reproxalap. That pressure has driven large volume and volatility. Put Options Flow Benzinga: What’s Going On
• Neutral Sentiment: Short-interest reports in recent feeds show inconsistent/zero values (likely data anomalies); treat reported short metrics cautiously until exchanges refresh official figures. No reliable signal from those entries.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.